1-800-516-8709

small logo

 

subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link
subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link
subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link
subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link
subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link
subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link
subglobal7 link | subglobal7 link | subglobal7 link | subglobal7 link | subglobal7 link | subglobal7 link | subglobal7 link
subglobal8 link | subglobal8 link | subglobal8 link | subglobal8 link | subglobal8 link | subglobal8 link | subglobal8 link

ADVANCED THERAPIES

Electrical shock ranks among the most devastating of all injuries: outright electrocution is a leading cause of death in some jobs, while survivors of severe electrical burns may undergo progressive tissue loss and often are unable to return to work. Historically, it was believed that the main cause of injury in electrical burns was the heating of tissue by the passage of current. CETRI researchers first challenged this assumption by demonstrating that much of the damage resulted from the opening and enlargement of pores in cell membranes due to high-intensity electric fields. This process of electroporation allows important ions to flow freely through the membrane, eventually resulting in cell death. A paper presenting evidence that this can occur even in the absence of thermal damage won the 1995 Lindberg Award of the American Burn Association.

On the basis of this understanding of electrical burns, CETRI researchers postulated a new type of treatment in which a surfactant already used for medical purposes, Poloxamer 188 (P-188), is administered to injured tissue to seal the membrane pores. The effectiveness of P-188 in this application has now been confirmed in both cell-culture and animal studies, and the U.S. Food and Drug Administration has given approval to begin clinical trials of the treatment.









©2010 Chicago Electrical Trauma Research Institute